Generic Drug Review June 2013

Despite some legislative gains, U.S. generic drug manufacturers still lag behind Europe in exploiting this potentially lucrative market.

One GDDP does not fit all, but studies show that these programs may reduce costs, increase compliance, and improve health outcomes.

Pharmacists should understand the various criteria, such as rate and extent of absorption, for creating lower-cost, equivalent medications.

In a wide-ranging interview, the GPhA's leader addresses the critical issues facing its member organizations, including biosimilars, the Affordable Care Act, drug-abuse deterrence, and pay-for-delay practices.

A looming slowdown in patent expirations is forcing manufacturers to seek other revenue sources.